Sugi Predict

Sugi Predict / Targets / PDLIM5

PDLIM5

PDZ and LIM domain protein 5 · Q96HC4 · PDLIM5 on Sugi Atlas →

0 patent compounds predicted against PDLIM5, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PDLIM5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
SCARFREE-001: Verteporfin for Scar Prevention PHASE2NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Immune Cell Response to Stimuli nanRECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Biocollection in MyeloDysplastic Syndrome (P-MDS) nanRECRUITING
Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia nanCOMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
The Activation of Hippo Pathway in Nasal Polyps nanUNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetic Variants in Linear Localized Scleroderma nanCOMPLETED
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia nanUNKNOWN
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
Genetic Study of Age-Related Macular Degeneration nanCOMPLETED
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs nanUNKNOWN
Speech and Short-term Memory Functions in Dyslexia: a Combined MEG and EEG Study nanUNKNOWN
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Exome Analysis in Hearing Impaired Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDLIM5 binder may also engage these)

ProteinNameSimilarity
Q62920 — 1.000 Q62920 →
Q8CI51 — 1.000 Q8CI51 →
Q9JKS4 — 0.999 Q9JKS4 →
O75112 — 0.997 O75112 →
Q9Z1Z9 — 0.996 Q9Z1Z9 →
Q2TCH4 — 0.996 Q2TCH4 →
Q6P7E4 — 0.994 Q6P7E4 →
P36202 — 0.994 P36202 →
Q3TJD7 — 0.994 Q3TJD7 →
Q679P3 — 0.993 Q679P3 →
Q5R7I1 — 0.992 Q5R7I1 →
Q66H76 — 0.992 Q66H76 →
P49023 — 0.992 P49023 →
P49024 — 0.991 P49024 →
Q8VI36 — 0.991 Q8VI36 →
Q3SX40 — 0.991 Q3SX40 →
Q8CHU3 — 0.990 Q8CHU3 →
Q5XI07 — 0.990 Q5XI07 →
F1MH24 — 0.990 F1MH24 →
Q9NR12 — 0.990 Q9NR12 →
Q2LC84 — 0.990 Q2LC84 →
O43150 — 0.990 O43150 →
P0C1X8 — 0.990 P0C1X8 →
Q9NQW6 — 0.990 Q9NQW6 →
Q9PW72 — 0.989 Q9PW72 →
Q2QMH1 — 0.989 Q2QMH1 →
O43294 — 0.989 O43294 →
Q8K0V4 — 0.989 Q8K0V4 →
Q9N261 — 0.989 Q9N261 →
Q62219 — 0.989 Q62219 →